Schizophrenia & Psychoses

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

By

Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

By

Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by FRAX tool.

Antipsychotic Nonadherence Due to Social Stigma

Antipsychotic Nonadherence Due to Social Stigma

By

Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

By

Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.

Schizophrenia Risk Linked to Cannabis Use

Schizophrenia Risk Linked to Cannabis Use

By

Cannabis is the most widely misused illicit drug.

Schizophrenia Associated With Years of Life Lost

Schizophrenia Associated With Years of Life Lost

By

Schizophrenia was associated with 13 to 15 years of potential life lost.

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

By

The risk for offspring's development of psychosis is connected to maternal weight gain during pregnancy.

Antipsychotic Adherence Boosted by Financial Incentives

Antipsychotic Adherence Boosted by Financial Incentives

By

A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.

Schizophrenia Symptoms Reduced by Vitamin B

Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.

FDA Approves New Schizophrenia Treatment for Adolescents

FDA Approves New Schizophrenia Treatment for Adolescents

By

The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

By

Researchers profiled which young people may do well after first-episode psychosis without medication.

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

By

These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.

Childhood Trauma, Depression Associated With Impaired Quality of Life in Schizophrenia

Childhood Trauma, Depression Associated With Impaired Quality of Life in Schizophrenia

By

Targeting negative symptoms in patients with schizophrenia may be more effective in improving patients' QoL.

Cardiometabolic Factors in Youth Schizophrenia Treatment

Cardiometabolic Factors in Youth Schizophrenia Treatment

By

Pretreatment cardiometabolic status to be taken into consideration for treatment of first episode psychosis.

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

By

Inability to interpret facial expressions may exacerbate psychotic symptoms, either indirectly via social defeat or directly by creating confusing interpersonal experiences.

Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment

Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment

By

Cardiac safety is integral to child and adolescent antipsychotic therapy.

Schizophrenia Linked to Type 2 Diabetes

Schizophrenia Linked to Type 2 Diabetes

Patients with early schizophrenia may have already started down the road to diabetes, even prior to actual diagnosis.

Antipsychotic Switching in Schizophrenia: Immediate vs Gradual Discontinuation

Antipsychotic Switching in Schizophrenia: Immediate vs Gradual Discontinuation

By

Both immediate and gradual discontinuation of the current antipsychotic medication are viable treatment options.

First-Episode Schizophrenia Approaches Aided by Guidelines Instrument

First-Episode Schizophrenia Approaches Aided by Guidelines Instrument

By

Clinical practice guidelines are important resources for early intervention in a first episode of schizophrenia.

Art Therapy as an Intervention for Psychosis

Art Therapy as an Intervention for Psychosis

By

A patient does not have to be verbal to benefit from art therapy.

Schizophrenia Patient Dead After UTI Treatment

Schizophrenia Patient Dead After UTI Treatment

By

This case offers evidence of the interaction between ciprofloxacin and clozapine.

Mindfulness Intervention Effective for Distressing Voices in Psychosis

Mindfulness Intervention Effective for Distressing Voices in Psychosis

By

Combined cognitive therapy and mindfulness can have lasting positive effects on behavior and mood.

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

By

PUFA supplementation offers little additional aid to psychosis when good psychosocial care is already sought.

Prolactin-Related Symptoms Decrease with Reduced Risperidone Dosage

Prolactin-Related Symptoms Decrease with Reduced Risperidone Dosage

By

Hyperprolactinemia should be monitored during long-term risperidone treatment.

Psychiatric Care for Incarcerated Patients

Psychiatric Care for Incarcerated Patients

By

According to one review, there are more individuals with serious mental illness in correctional institutions than in all US state hospitals.

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.

Impaired Auditory 40-Hz Steady-State Responses Noted in Schizophrenia

Impaired Auditory 40-Hz Steady-State Responses Noted in Schizophrenia

By

40-Hz ASSR spectral power and phase-locking deficits could be useful probes for assessing circuit dysfunctions in the disorder.

Prediabetic Markers May Be Linked With First-Episode Psychosis

Prediabetic Markers May Be Linked With First-Episode Psychosis

By

The findings might help to explain the increased prevalence of type 2 diabetes in patients with schizophrenia.

Significant Cognitive Impairment in Those At High Risk of Psychosis

Significant Cognitive Impairment in Those At High Risk of Psychosis

By

Studying cognition deficits during the clinical high risk period allows researchers to observe cognitive defects before chronicity and long-term medication use obscure the core deficits.

Study Elucidates Role of DIXDC1 Gene in Psychiatric Pathogenesis

Study Elucidates Role of DIXDC1 Gene in Psychiatric Pathogenesis

By

Dixdc1 knockout mice demonstrated behaviors suggestive of depression, anxiety, and impaired social behavior.

Sign Up for Free e-newsletters